Skip to main content

Andrew Benjamin Nixon

Professor in Medicine
Medicine, Medical Oncology
Duke Box 2631, Durham, NC 27710
133 Jones, Research Drive, Durham, NC 27710


Andrew Nixon, PhD, MBA (Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Current Appointments & Affiliations

Professor in Medicine · 2021 - Present Medicine, Medical Oncology, Medicine
Member of the Duke Cancer Institute · 1998 - Present Duke Cancer Institute, Institutes and Centers

Education, Training & Certifications

Duke University · 2007 M.B.A.
Wake Forest University · 1997 Ph.D.